Cargando…

Molecular Chaperone GRP94/GP96 in Cancers: Oncogenesis and Therapeutic Target

During tumor development and progression, intrinsic and extrinsic factors trigger endoplasmic reticulum (ER) stress and the unfolded protein response, resulting in the increased expression of molecular chaperones to cope with the stress and maintain tumor cell survival. Heat shock protein (HSP) GRP9...

Descripción completa

Detalles Bibliográficos
Autores principales: Duan, Xiaofeng, Iwanowycz, Stephen, Ngoi, Soo, Hill, Megan, Zhao, Qiang, Liu, Bei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8062746/
https://www.ncbi.nlm.nih.gov/pubmed/33898309
http://dx.doi.org/10.3389/fonc.2021.629846
_version_ 1783681825541980160
author Duan, Xiaofeng
Iwanowycz, Stephen
Ngoi, Soo
Hill, Megan
Zhao, Qiang
Liu, Bei
author_facet Duan, Xiaofeng
Iwanowycz, Stephen
Ngoi, Soo
Hill, Megan
Zhao, Qiang
Liu, Bei
author_sort Duan, Xiaofeng
collection PubMed
description During tumor development and progression, intrinsic and extrinsic factors trigger endoplasmic reticulum (ER) stress and the unfolded protein response, resulting in the increased expression of molecular chaperones to cope with the stress and maintain tumor cell survival. Heat shock protein (HSP) GRP94, also known as GP96, is an ER paralog of HSP90 and has been shown to promote survival signaling during tumor-induced stress and modulate the immune response through its multiple clients, including TLRs, integrins, LRP6, GARP, IGF, and HER2. Clinically, elevated expression of GRP94 correlates with an aggressive phenotype and poor clinical outcome in a variety of cancers. Thus, GRP94 is a potential molecular marker and therapeutic target in malignancies. In this review, we will undergo deep molecular profiling of GRP94 in tumor development and summarize the individual roles of GRP94 in common cancers, including breast cancer, colon cancer, lung cancer, liver cancer, multiple myeloma, and others. Finally, we will briefly review the therapeutic potential of selectively targeting GRP94 for the treatment of cancers.
format Online
Article
Text
id pubmed-8062746
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80627462021-04-24 Molecular Chaperone GRP94/GP96 in Cancers: Oncogenesis and Therapeutic Target Duan, Xiaofeng Iwanowycz, Stephen Ngoi, Soo Hill, Megan Zhao, Qiang Liu, Bei Front Oncol Oncology During tumor development and progression, intrinsic and extrinsic factors trigger endoplasmic reticulum (ER) stress and the unfolded protein response, resulting in the increased expression of molecular chaperones to cope with the stress and maintain tumor cell survival. Heat shock protein (HSP) GRP94, also known as GP96, is an ER paralog of HSP90 and has been shown to promote survival signaling during tumor-induced stress and modulate the immune response through its multiple clients, including TLRs, integrins, LRP6, GARP, IGF, and HER2. Clinically, elevated expression of GRP94 correlates with an aggressive phenotype and poor clinical outcome in a variety of cancers. Thus, GRP94 is a potential molecular marker and therapeutic target in malignancies. In this review, we will undergo deep molecular profiling of GRP94 in tumor development and summarize the individual roles of GRP94 in common cancers, including breast cancer, colon cancer, lung cancer, liver cancer, multiple myeloma, and others. Finally, we will briefly review the therapeutic potential of selectively targeting GRP94 for the treatment of cancers. Frontiers Media S.A. 2021-04-09 /pmc/articles/PMC8062746/ /pubmed/33898309 http://dx.doi.org/10.3389/fonc.2021.629846 Text en Copyright © 2021 Duan, Iwanowycz, Ngoi, Hill, Zhao and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Duan, Xiaofeng
Iwanowycz, Stephen
Ngoi, Soo
Hill, Megan
Zhao, Qiang
Liu, Bei
Molecular Chaperone GRP94/GP96 in Cancers: Oncogenesis and Therapeutic Target
title Molecular Chaperone GRP94/GP96 in Cancers: Oncogenesis and Therapeutic Target
title_full Molecular Chaperone GRP94/GP96 in Cancers: Oncogenesis and Therapeutic Target
title_fullStr Molecular Chaperone GRP94/GP96 in Cancers: Oncogenesis and Therapeutic Target
title_full_unstemmed Molecular Chaperone GRP94/GP96 in Cancers: Oncogenesis and Therapeutic Target
title_short Molecular Chaperone GRP94/GP96 in Cancers: Oncogenesis and Therapeutic Target
title_sort molecular chaperone grp94/gp96 in cancers: oncogenesis and therapeutic target
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8062746/
https://www.ncbi.nlm.nih.gov/pubmed/33898309
http://dx.doi.org/10.3389/fonc.2021.629846
work_keys_str_mv AT duanxiaofeng molecularchaperonegrp94gp96incancersoncogenesisandtherapeutictarget
AT iwanowyczstephen molecularchaperonegrp94gp96incancersoncogenesisandtherapeutictarget
AT ngoisoo molecularchaperonegrp94gp96incancersoncogenesisandtherapeutictarget
AT hillmegan molecularchaperonegrp94gp96incancersoncogenesisandtherapeutictarget
AT zhaoqiang molecularchaperonegrp94gp96incancersoncogenesisandtherapeutictarget
AT liubei molecularchaperonegrp94gp96incancersoncogenesisandtherapeutictarget